Lastly, using a syngeneic murine model, SGLT2 inhibitors in concert with 2’3’-cGAMP constrained osteosarcoma tumour growth and potentiated CD45+ CD4+/CD45+ CD8+ T-lymphocyte infiltration at tumour sites. Here, SLC5A2 is linked to osteosarcoma.